Alzheon more than 20 years of drug discovery and development experience in both biotechnology and pharmaceutical drug development. He has held senior leadership positions in drug development at several biotechnology companies including CoMentis and NormOxys, focusing on Alzheimer’s disease and oncology, respectively. As Senior Vice President of Discovery and Preclinical Drug Development at CoMentis, Dr. Hey served as the pivotal senior leader and drug development officer responsible for the beta-secretase inhibitor drug development program for Alzheimer’s disease. In this role, he built a drug discovery and drug development team optimization facility, and led a team of over 25 scientists responsible for all key aspects of early drug development, including: PK/PD, biochemistry, in vitro and in vivo pharmacology, in vitro and in vivo ADME, bioanalytical, preclinical safety, safety pharmacology, translational medicine, medicinal chemistry and early clinical development. This work successfully culminated in the first clinically tested beta secretase candidate, as well as an industry-leading $1.1 billion transaction with Astellas Pharma in 2008.

  Alzheon more than 20 years of drug discovery and development experience in both biotechnology and pharmaceutical drug development. He has held senior leadership positions in drug development at several biotechnology companies including CoMentis and NormOxys, focusing on Alzheimer’s disease and oncology, respectively. As Senior Vice President of Discovery and Preclinical Drug Development at CoMentis, Dr. Hey served as the pivotal senior leader and drug development officer responsible for the beta-secretase inhibitor drug development program for Alzheimer’s disease. In this role, he built a drug discovery and drug development team optimization facility, and led a team of over 25 scientists responsible for all key aspects of early drug development, including: PK/PD, biochemistry, in vitro and in vivo pharmacology, in vitro and in vivo ADME, bioanalytical, preclinical safety, safety pharmacology, translational medicine, medicinal chemistry and early clinical development. This work successfully culminated in the first clinically tested beta secretase candidate, as well as an industry-leading $1.1 billion transaction with Astellas Pharma in 2008.